233 related articles for article (PubMed ID: 28717040)
1. Flucloxacillin Results in Suboptimal Plasma Voriconazole Concentrations.
Muilwijk EW; Dekkers BGJ; Henriet SSV; Verweij PE; Witjes B; Lashof AMLO; Groeneveld GH; van der Hoeven J; Alffenaar JWC; Russel FGM; van de Veerdonk F; Brüggemann RJM
Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28717040
[TBL] [Abstract][Full Text] [Related]
2. Impact of CYP2C19, CYP3A4, ABCB1, and FMO3 genotypes on plasma voriconazole in Thai patients with invasive fungal infections.
Chuwongwattana S; Jantararoungtong T; Prommas S; Medhasi S; Puangpetch A; Sukasem C
Pharmacol Res Perspect; 2020 Dec; 8(6):e00665. PubMed ID: 33124772
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic drug monitoring and safety of intravenous voriconazole formulated with sulfobutylether β-cyclodextrin in haematological patients with renal impairment.
Kim SH; Kwon JC; Park C; Han S; Yim DS; Choi JK; Cho SY; Lee HJ; Park SH; Choi SM; Choi JH; Yoo JH; Lee DG; Lee JW
Mycoses; 2016 Oct; 59(10):644-51. PubMed ID: 27324913
[TBL] [Abstract][Full Text] [Related]
4. Pediatric Clinical Pharmacology of Voriconazole: Role of Pharmacokinetic/Pharmacodynamic Modeling in Pharmacotherapy.
Kadam RS; Van Den Anker JN
Clin Pharmacokinet; 2016 Sep; 55(9):1031-43. PubMed ID: 26979736
[TBL] [Abstract][Full Text] [Related]
5. Optimization of Voriconazole Therapy for the Treatment of Invasive Fungal Infections in Adults.
Mangal N; Hamadeh IS; Arwood MJ; Cavallari LH; Samant TS; Klinker KP; Bulitta J; Schmidt S
Clin Pharmacol Ther; 2018 Nov; 104(5):957-965. PubMed ID: 29315506
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic drug monitoring of voriconazole helps to decrease the percentage of patients with off-target trough serum levels.
Guinea J; Escribano P; Marcos-Zambrano LJ; Peláez T; Kestler M; Muñoz P; Vena A; López-Fabal F; Bouza E
Med Mycol; 2016 May; 54(4):353-60. PubMed ID: 26739190
[TBL] [Abstract][Full Text] [Related]
7. Fulminant mulch pneumonitis in a previously healthy child.
Maaloul I; Ameur SB; Chabchoub I; Kolsi R; Bahloul M; Kamoun T; Bouaziz M; Hachicha M
Arch Pediatr; 2018 Nov; 25(8):495-496. PubMed ID: 30340947
[TBL] [Abstract][Full Text] [Related]
8. Interaction between posaconazole and flucloxacillin in a lung transplant patient: decrease in plasma exposure of posaconazole and possible undertreatment of invasive aspergillosis: case report.
Verfaillie S; Godinas L; Spriet I; Vos R; Verleden GM
BMC Pulm Med; 2022 Mar; 22(1):110. PubMed ID: 35346142
[TBL] [Abstract][Full Text] [Related]
9. Broad-spectrum azoles and flucloxacillin: a dangerous match.
Vangheluwe T; Van Hoecke F; Dumoulin A; Vogelaers D
Eur J Clin Microbiol Infect Dis; 2022 Jan; 41(1):153-154. PubMed ID: 34494173
[TBL] [Abstract][Full Text] [Related]
10. Serum Aspergillus fumigatus-specific IgG antibody decreases after antifungal treatment in chronic pulmonary aspergillosis patients.
Yao Y; Zhou H; Yang Q; Lu G; Yu Y; Shen Y; Zhou J
Clin Respir J; 2018 Apr; 12(4):1772-1774. PubMed ID: 28862383
[No Abstract] [Full Text] [Related]
11. Utility of voriconazole therapeutic drug monitoring: a meta-analysis.
Luong ML; Al-Dabbagh M; Groll AH; Racil Z; Nannya Y; Mitsani D; Husain S
J Antimicrob Chemother; 2016 Jul; 71(7):1786-99. PubMed ID: 27165788
[TBL] [Abstract][Full Text] [Related]
12. It cuts both ways: A single-center retrospective review describing a three-way interaction between flucloxacillin, voriconazole and tacrolimus.
Burrows FS; Carlos LM; Stojanova J; Marriott DJE
Int J Antimicrob Agents; 2023 Sep; 62(3):106908. PubMed ID: 37385563
[TBL] [Abstract][Full Text] [Related]
13. Clinical outcomes of lung-transplant recipients treated by voriconazole and caspofungin combination in aspergillosis.
Thomas A; Korb V; Guillemain R; Caruba T; Boussaud V; Billaud E; Prognon P; Begué D; Sabatier B
J Clin Pharm Ther; 2010 Feb; 35(1):49-53. PubMed ID: 20175811
[TBL] [Abstract][Full Text] [Related]
14. Invasive pulmonary aspergillosis due to azole-resistant Aspergillus lentulus.
Tetsuka N; Yaguchi T; Machida H; Ito S; Miyairi I
Pediatr Int; 2017 Mar; 59(3):362-363. PubMed ID: 28317305
[No Abstract] [Full Text] [Related]
15. Twelve-month clinical outcomes of 206 patients with chronic pulmonary aspergillosis.
Bongomin F; Harris C; Hayes G; Kosmidis C; Denning DW
PLoS One; 2018; 13(4):e0193732. PubMed ID: 29634721
[TBL] [Abstract][Full Text] [Related]
16. Treatment of chronic pulmonary aspergillosis with voriconazole: review of a case series.
Cucchetto G; Cazzadori A; Conti M; Cascio GL; Braggio P; Concia E
Infection; 2015 Jun; 43(3):277-86. PubMed ID: 25432571
[TBL] [Abstract][Full Text] [Related]
17. Interaction between flucloxacillin and azoles: Is isavuconazole next?
Van Daele R; Wauters J; Vandenbriele C; Lagrou K; Vos R; Debaveye Y; Spriet I
Mycoses; 2021 Dec; 64(12):1508-1511. PubMed ID: 34553797
[TBL] [Abstract][Full Text] [Related]
18. Invasive fungal consecutive infections in a patient with acute myeloid leukaemia.
Safai Nodeh SR; Dehghan Manshadi SA; Jahanbin B; Khodaveisi S; Giasvand F; Seifi A; Salehi M
Niger J Clin Pract; 2019 Apr; 22(4):582-584. PubMed ID: 30975967
[TBL] [Abstract][Full Text] [Related]
19. Infantile Aspergillus fumigatus ventriculitis successfully treated with monitoring of plasma and cerebrospinal fluid voriconazole concentration level.
Furudate A; Hirose S; Abe K; Kawashima A; Hashimoto K; Yamazaki S; Kamei K; Ishiwada N; Hamada H; Sato M
J Infect Chemother; 2020 Jan; 26(1):132-135. PubMed ID: 31350185
[TBL] [Abstract][Full Text] [Related]
20. Prophylactic administration of voriconazole with two different doses for invasive fungal infection in children and adolescents with acute myeloid leukemia.
Sano H; Kobayashi R; Hori D; Kishimoto K; Suzuki D; Yasuda K; Kobayashi K
J Microbiol Immunol Infect; 2018 Apr; 51(2):260-266. PubMed ID: 27329132
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
